2013 (2) 

(35) 


 _ 


     
Tishreen University Journal for Research and Scientific Studies - Health Sciences Series Vol. (35) No. (2) 2013

  !
   : 

*
 "  

( 2013/ 3 / 24 ,-  .+)* .2012 / 11 / 4 $

%
& )

/10 

   !"# 

   
  
   
  
2 ./%0 1 
 2+
3, %$ .  -)  *)  *+, *) (%& $'
#$%
> #  #; <=.9 # :  8$   / $ 5 .

60 5' 
C   3& D 5 3 @/&+ ?% ./A B" # 5; /0  .  ? =;
%23.91  /  2+
  %71.73  E 2$#, #$% -)% + : ..#
./', %4.34   
 5 ,

2 ,/0  ,#$%% ,

 :2


. 3*8!
3  367
3
4
5
*3 *

39
  #$% -)   2 :


2013 (2) 

(35) 


 _ 


     
Tishreen University Journal for Research and Scientific Studies - Health Sciences Series Vol. (35) No. (2) 2013

Erysipelas: Epidemiology
and role of lincomycin in the management
Dr. Roula Baddour*

(Received 4 / 11 / 2012. Accepted 24 / 3 / 2013)

ABSTRACT

The aim of this research is to study statistically erysipelas cases and its precipitating
factors and also to determine the possibility of considering intramuscular injection of
lincomycin as an effective treatment of uncomplicated erysipelas instead of intravenous
penicillin G.
60 cases of erysipelas were studied and evaluated. There was no significant relation
to age, sex and site of infection. The most affected sites were lower limbs, then face, and
upper limbs.
The most important risk factors were fungal intertrigo, vascular impairment and
finally diabetes mellitus.
The response to lincomycin treatment was excellent in 71.71%, intermediate in
23.91% of patients, while there was no response in only 4.34% of cases.

Keywords: erysipelas, Lincomycin, risk factors, epidemiology

*
Assistant Professor, Dermatology Department, Faculty of Medicine, Tishreen University, Lattakia,
Syria .

40
 Tishreen University Journal. Health Sciences Series 2013 (2)  (35) % 
 5%
O  %

:9
AO+ @%/ 3 ,9 2+
  1   $ O  % 29  
 
T > 2 
 SA   E 
30 D 3 (
 2  .  -) 3'%
D 3, O =.3
$ . ' ) ',  " 
,
O , 
 
& 


3, 2& # (? 3, <&   # ,[1]  
 ,E$ >/$ < 2', 
: 2)
2+

[2] (2+
  %85)O #; 3 %A /;
3& D  0 @ # 2+
 @%1: 3, O 
 
  & 
)) $ ; !"# (8#$ E <& 5=A A% :  #   " : # ./A B"
[3] .##   $$ :  ./0 #; 
 2+
 >, 3$O
С В /$  2 ' O =: #O  ( ß5 % 
Α  ' 2# 2+
 5T 3, 
2
' ', 
 2+
D 3,  '$ 2#  #" 
 2  D 3, .[4] ᴅ
[5]>
D
 
 =A  $: 
9 )0  ) @+ 2 & $ Y$ +
[2]

E) , # E#9 ,3 % @ ,$

 ,.%0 Z$ @  
 >A @
[6]..2O
 [  , ' 
,> .  0 ,2
G %$ / , &
\ 
\ .

\ 
\ # : @, 8 @ 3 2 ' # :-)
# !" ,5: 4^2  & 2) 
 : @ , 24 )0
 % 20^12  
A0 
C1 : (2 3 % E  24 )0 51 4.5^3) %; ., -) 
  "$ #, /0 2)   A 
 2$# 
3, : .( 20^10)& 2)
/ # %$  8
 
3, .* 15    #" A$_ 2 %; ., -) O
 $ : A$ ) A%   `% 150  #  2 #
:  $%## E#$% 2# / # # .[8] [7] (2 3 % E  24 /[3^2 )
b, 3E$ -) 
3, .   C" ?
&  "  .[9] 5A >/   %& $'
#$%
[2]AO+ 3     2) T : -)   72  
 
1 -)%  8#$ " ,2+
  %23   = 3  8#$ $  O9 @
[2] .=% %$ / -) c&0 B' D  (0  @ 3, 8#$  : 3,#

:<-
:; 
:;
#,
 2 
\ .  -) 3'% AO+ @%/ 3 ,9 2+
  1 
 
\
3'% 

 " : 3d $  %  %

   + # ?A%# AO+   T$
/0  
 $$ :  
% 3) 0# %& $'
#$% -) % &
.-)% + 3, !" d + C" ',

41
  #$% -)   2 :


.8$   @
 E   
 D 
  ^
.    
% O #; 2&  ^
.A%0  A C" d   
 -) 3, #$% ,  ^

:>
 
=
7

 2+
cE 
 5 
=") 3, 0  % 2 
 & %   2
& 0 5  5 0 2+   
 & E, 5 !"     % D; 
.+ 3, %A A%0  A C" /    " ,   #$% 

 "
? 8
8$  5+
e
2', 9 #
  
:-)% +
(5: 4^2 )0 
) E
(c: )0 
)/
 5 

:*
 @

^2000 A 3, =") 3, 0  % 2 

 3 % 3 #O   2:
.   .:  60  
 
 A%0  % Dd  19150 2%O 8^2003 7
%0.31 C =

? 
4
5
  
 . BC (1).

 $ 

 &  A%0  % #O 
%0.31 60 19150

 $   (2$ 5   2, % & <E 5 ',  @
 
   :
$ 80 

A 3, 2 :  5 

3, (%15)$ 40^45  A 3, 
$ %: 
$ 10^15  5^10

42
 Tishreen University Journal. Health Sciences Series 2013 (2)  (35) % 
 5%
O  %

 
2
6 
 BC (2).

$  A $  A $  A

% &  % &  % & 
8,33 5 60^65 6.66 4 30^35 1.66 1 1^5
10 6 65^70 6.66 4 35^40 0 0 5^10
3.33 2 70^75 15 9 40^45 0 0 10^15
1.66 1 75^80 6.66 4 45^50 5 3 15^20
11.66 7 50^55 8.33 5 20^25
8.33 5 55^60 6.66 4 25^30
.(43,008) $ 43 ?$: Z$ 
 @ D  / @
$ :
.A%0  2,  . cE + $:  5T$ <E% <&0 2 # 2$# " ,
. $9  #"   >A # 5 8$  / 
 

F
6 
 BC (3).

 $ $9   $ #"  3%# & 

%46.67 28 %53.33 32 60

$ ($: 19   #" 23)0O 42   3 > 2$# '%, 9 <= >% , :
$ .: ,58  @: 3%A / : .: ,( $ 7  #" 9) 0O 16   3 5 ' 2$#
.   !"#  
    (?  2  $ (%96.66=26.66+70)

   %
 BC (4) .

$ > $ 5 ' $ ? $  <&

    8$
38.33 23 15 9 0 0 0 0 #"
31.66 19 11.66 7 1.66 1 1.66 1 $
70 42 26.66 16 1.66 1 1.66 1 c

: $ 0+ O = @

  < .d# 0 5 0$ 9 # 8$  =)  
P^ Value = 0.498 .$ =)  5  ' DA '$ !" 0.05  #: 3 
 =
. 0+ 
 =  .: 0.136 . ?= : $  1 /+  @
 $=  0+
 >% , 
 + ? 8  .$ 1 /+  '$ !" .0.05  #: 3  (0.615

43
  #$% -)   2 :


" : $ 4   4  ./, B"   $ 3    .#   '%, /0
.
 :  2 O ', A%

9-

 71
.
? BC (5) .

$ c D @/& A " ./, B" .# 9

 3& 3 8$
23.33 14 4 5 0 4 1 #"
16.66 10 1 1 1 4 3 $:
40.00 24 5 6 1 8 4 c
8.33 10 1.66 13.33 6.66 % $
?% ./A B" : % < (  < ', 2% 2+
  %40 $ : .:
..# ?% (3& D 5  (3 @/&+
=: .: ( P =0.202) 
  / $ 5 ', 29 8$  =)  
.0.05
:
   
@
-)  5  
   
  `% 600  %& $'
#$%  5
(.  0  =% 0 <$ ?A 5: 5   * 2 3 `% 500 ; /  ,&) .,

(#" 19 $: 14) & 33  E $ 2$#  .(#" 24  $: 22) & 46  !"
(#" 5  $ 6) & 11  ?$: 
3, .*' 5: 4 )0 3,  2) <  


: / 5 ($:  #") $ &  ?$: 

3, .    5: 6 )0 d/: #O 
 "

2$#, ( $ 4  #" 4) & 8  : .AO 3,   G %$ /  $/&  
 .:
5/    "$ 5AO 5, BA @%= %  .  @/& ', ,&   

%$ 5 2, AA0 5  A/: 5T 6 5   &  '  :,  G %$
.:  A : !$,)# D
<

   

JK 
L "
. BC (6).

c $ 5  $ / $ E +

    &
25 2.17 1 10.86 5 41.30 19 #"
21 2.17 1 13.04 6 30.43 14 $
46 4.34 2 23.91 11 71.73 33 c
#$%  &  71%  #:  E + 2$#    T
)$ #
%4  /', 2$# + 5  $

44
 Tishreen University Journal. Health Sciences Series 2013 (2)  (35) % 
 5%
O  %

>,  5   $9  #"    + 3$  >A% 3

9 0+  
.( P=0.48)8$%  + !% 
 5
:*

  8d + $ d CA #   % D;  

 
 $ DA0$   
.$   O 2+
 + 
# 0: 20  & +
3, 9 C" cO  T$ @o 1 " ./A B" : n ', /0 
 ,8#$ 3, 5  
 $ 3, ?%, 3 @/&+ : ,
%  0  #O  ($
..# 5    3, 3& D 3d
.  O $ 2$#, /%0 1 2+
 '$ 5 ', ,#$%  >% , :

: 9



/ 
 A Z$ 2$# [10] 2011 ; $# 3, 2: $,   $ $' 
 
; $ : .$ 43$ 3, # , ($ 63 D% /  5  # " (
/0  $'   ,2+
  %96 $  2o% $ %83.3 $ 5  2$#, 3%A /
, (./A B" % 5   " : %  5  2+
  %76     ',
5  3 @/&+ ?% ./A B" : % #  (&  %40 $ $   C" 2 
..# C   3& D
/  
: < , $ 54.5 /  #, [11] 2010 5  $   :
. %62  0  2   %76 $ 3%A
58.6 n /  :  [12] 2010 5 E  3, 2:   < $' 
.%36.2 $ 3 @/&+ ?% %41 $ .#  5; /0  : $

:
 "

. ) 3, #$% , !"# 

 
3,  % 5   >  Z$$
:3%  3$
.
% @ % 0 /'$ # = " ./, B" .:  5  5  # /& ^
 /%0 1 
 2+
3, !"  .  %$%  # %& $'
#$% -) 3$ ^
.   D % !" C, 
.OA " %
 @; 
  -)%  1 2+
   2  ^

45
  #$% -)   2 :


:M


1- BOLOGNIA, J;JORRIZZO,J;RAPINI,R. Dermatology.2 ˚.ed, Mosby,Elsevier,

Spain,2008:2391.
2- DUBERTRET,L.;.ARACTANGI,S.; BACHELEZ,H.; BODEMER,C.;CHOSIDOW,O.;
CRIBIER,B.; JOLY,P. Therapeutique dermatologique.2 ͦ.ed, Medecine-sciences,
Flammarion, Paris, 2001:1288.
3-DUPUY,A;BENCHIKHI,H;ROUJEAU,JC .Risk factors for erysipelas of the
leg(cellulitis):case control study.Br Med J,1999,318:1591-1594.
4-SAURAT,J.H;GROSSHAND,E;LAUGIER,P;LACHAPELLE,JM.Dermatologie et
infections sexuellement transmissibles.4 ͦ.ed,Masson,Paris,2004,1131.
5-OIEN,RF;AKESSON ,N.Bacterial cultures,rapid strep test, and antibiotic treatment in
infected hard-to-heal ulcers in primary care.Scand J Prim Health Care,2012 Dec
30,40:245-8.
6-WOLFF,K;JOHNSON,R.FITZPATRICK’S.Clinical dermatology.fifth ed,McGraw-Hill,
U.S.A, 2005,1085.
7-BERNARD,P;PLANTIN,P;ROGER,H.Roxithromycin versus penicillin in the treatment
of erysipelas in adults: a comparative study.Br J Dermatol,1992,127:155-159.
8-BERNARD,P;RISSE,L; BONNETBLANC,JM.Traitement des dermohypodermites
aigues bacteriennes de l’adulte par la pristinamycine. Etude ouverte chez 42
malades.Ann Dermatol Vénéréol,1996,123:16-20.
9-LUCHT,F. Quelle prise en charge pour l’érysipèle ?Traitement antibiotique; molecules;
voies d’administration.Médecine et maladies infectieuses.vol˚30,N˚4.Nov 2000,343-
346.
10-LARIVIERE,D.prise en charge de l’erysipele en médecine générale: enquête de
pratique.La revue de Médecine interne,France,vol.32,N ͦ. 12,2011,730-735.
11-KRASAGAKIS,K. Analysis of epidemiology,clinical features and management of
erysipelas.Int J Dermatol Greece,vol.49,N ͦ.9,2010,1012-7.
12-PERETRA DE GODOY,JM.Epidemiological data and comorbidities of428 patients
hospitalized with erysipelas.Angiology.Brazil,Vol.61,N ͦ.5,2010,492-4.

46